NASDAQ:HALO Halozyme Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $46.90 +0.10 (+0.21%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$46.75▼$48.5450-Day Range$37.35▼$48.3052-Week Range$31.36▼$48.58Volume3.19 million shsAverage Volume990,508 shsMarket Capitalization$6.47 billionP/E Ratio15.69Dividend YieldN/APrice Target$53.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Stock Forecast (MarketRank)Overall MarketRank™2.39 out of 5 starsMedical Sector202nd out of 1,418 stocksBiological Products, Except Diagnostic Industry30th out of 216 stocksAnalyst Opinion: 2.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 - 2.5 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.20, Halozyme Therapeutics has a forecasted upside of 13.4% from its current price of $46.90.Amount of Analyst CoverageHalozyme Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesHalozyme Therapeutics has received 464 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHalozyme Therapeutics has received 207 “underperform” votes. (Add your “underperform” vote.)Community SentimentHalozyme Therapeutics has received 69.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions92.53% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 50.00% in the coming year, from $2.08 to $3.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 15.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 15.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 9.46.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.71. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 33.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Halozyme Therapeutics (NASDAQ:HALO)Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.Read More HALO Stock News HeadlinesJune 13, 2022 | uk.finance.yahoo.comFour reasons why the Halozyme Therapeutics (NSQ:HALO) share price could moveJune 11, 2022 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $50.14 Consensus Price Target from BrokeragesJune 9, 2022 | finance.yahoo.comHalozyme Therapeutics (HALO) Up 19.8% Since Last Earnings Report: Can It Continue?June 9, 2022 | morningstar.comHalozyme Therapeutics Inc - Stock NewsJune 8, 2022 | finance.yahoo.comHalozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceJune 7, 2022 | finance.yahoo.comHalozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyJune 6, 2022 | finance.yahoo.comHalozyme Delivers for Big MoneyJune 2, 2022 | americanbankingnews.comHead to Head Contrast: Halozyme Therapeutics (NASDAQ:HALO) and Dyadic International (NASDAQ:DYAI)June 1, 2022 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High at $48.58May 24, 2022 | finance.yahoo.comHalozyme Completes Antares Pharma AcquisitionMay 20, 2022 | nasdaq.comFirst Week of July 15th Options Trading For Halozyme TherapeuticsMay 19, 2022 | finance.yahoo.com5 Reasons Why You Should Add Halozyme (HALO) to Your PortfolioMay 11, 2022 | finance.yahoo.comHalozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y RevenuesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees145Year Founded1998Company Calendar Last Earnings5/10/2022Today6/24/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$53.20 High Stock Price Forecast$60.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+13.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.989990 Trailing P/E Ratio15.69 Forward P/E Ratio22.55 P/E Growth0.71Net Income$402.71 million Net Margins92.23% Pretax Margin62.52% Return on Equity132.71% Return on Assets25.45% Debt Debt-to-Equity Ratio3.03 Current Ratio8.85 Quick Ratio8.42 Sales & Book Value Annual Sales$443.31 million Price / Sales14.59 Cash Flow$2.05 per share Price / Cash Flow22.89 Book Value$1.40 per share Price / Book33.50Miscellaneous Outstanding Shares137,950,000Free Float134,777,000Market Cap$6.47 billion OptionableOptionable Beta1.23 Social Links Halozyme Therapeutics Frequently Asked Questions Should I buy or sell Halozyme Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock. View analyst ratings for Halozyme Therapeutics or view top-rated stocks. What is Halozyme Therapeutics' stock price forecast for 2022? 4 Wall Street research analysts have issued 1-year price targets for Halozyme Therapeutics' stock. Their HALO stock forecasts range from $42.00 to $60.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $53.20 in the next year. This suggests a possible upside of 13.4% from the stock's current price. View analysts' price targets for Halozyme Therapeutics or view top-rated stocks among Wall Street analysts. How has Halozyme Therapeutics' stock performed in 2022? Halozyme Therapeutics' stock was trading at $40.21 at the beginning of 2022. Since then, HALO stock has increased by 16.6% and is now trading at $46.90. View the best growth stocks for 2022 here. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Halozyme Therapeutics. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by $0.02. The biopharmaceutical company had revenue of $117.30 million for the quarter, compared to analyst estimates of $128.25 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 132.71% and a net margin of 92.23%. The company's quarterly revenue was up 31.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS. View Halozyme Therapeutics' earnings history. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics updated its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share guidance of $2.05-$2.20 for the period, compared to the consensus EPS estimate of $2.23. The company issued revenue guidance of $530.00 million-$560.00 million, compared to the consensus revenue estimate of $566.18 million. Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the following people: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., Pres, CEO & Director (Age 59, Pay $1.65M)Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 58, Pay $779.55k) (LinkedIn Profile)Ms. Nicole LaBrosse, Sr. VP & CFO (Age 39)Ms. Melinda Hutcheon, Director of Investor Relations & Corp. CommunicationsMr. Mark Snyder Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.Ms. Amy Marinne Fox, VP of HRDr. Steve Knowles MBBS, Chief Medical OfficerMr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project ManagementDr. Christopher Bryant Ph.D., Sr. VP of Technical Operations & Chief Manufacturing Officer (Age 61) What is Helen Torley's approval rating as Halozyme Therapeutics' CEO? 12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees. Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS). View all of HALO's competitors. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.62%), William Blair Investment Management LLC (3.88%), Invesco Ltd. (3.86%), Snyder Capital Management L P (2.93%), Northern Trust Corp (1.63%) and Loomis Sayles & Co. L P (1.59%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre. View institutional ownership trends for Halozyme Therapeutics. Which major investors are selling Halozyme Therapeutics stock? HALO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Skandinaviska Enskilda Banken AB publ , Vanguard Group Inc., Invesco Ltd., Federated Hermes Inc., UBS Group AG, WINTON GROUP Ltd, and Eagle Asset Management Inc.. Company insiders that have sold Halozyme Therapeutics company stock in the last two years include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre. View insider buying and selling activity for Halozyme Therapeutics or view top insider-selling stocks. Which major investors are buying Halozyme Therapeutics stock? HALO stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Loomis Sayles & Co. L P, Bernzott Capital Advisors, Sectoral Asset Management Inc., GW&K Investment Management LLC, Russell Investments Group Ltd., First Light Asset Management LLC, and Renaissance Technologies LLC. View insider buying and selling activity for Halozyme Therapeutics or or view top insider-buying stocks. How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $46.90. How much money does Halozyme Therapeutics make? Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $6.47 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $2.989990 on an earnings per share basis. How many employees does Halozyme Therapeutics have? Halozyme Therapeutics employs 145 workers across the globe. Does Halozyme Therapeutics have any subsidiaries? The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.Read More When was Halozyme Therapeutics founded? Halozyme Therapeutics was founded in 1998. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for Halozyme Therapeutics is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at [email protected], or via fax at 858-704-8311. This page (NASDAQ:HALO) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here